Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK industry challenges generalisation of studies slamming monitoring

This article was originally published in Clinica

Executive Summary

Researchers questioning the clinical value and cost-effectiveness of blood glucose self-monitoring in type 2 (non-insulin-dependent) diabetes have rekindled a decade-long debate on the issue. The main findings of two studies published today by the British Medical Journal (BMJ) are that routine testing may be wasting around £100m ($198m) a year, with little glycaemic control benefit and, reputedly, worse quality of life.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT046776

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel